Search | Clinical Trials Finder

Conditions: Infection, Human Immunodeficiency Virus I
Interventions: LEXIVA (GW433908), Ritonavir; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • Oakland, California + 10 more

Conditions: Athletic Injuries
Interventions: Diclofenac hydroxyethylpyrrolidine; Drug
Lead sponsor: IBSA Institut Biochimique SA; Industry
Eligibility: 6 Years to 16 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 10
States / cities: Little Rock, Arkansas • St. Petersburg, Florida • Marietta, Georgia + 5 more

Conditions: Detrusor Hyperreflexia
Interventions: Oxybutynin; Drug
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 6 Years to 15 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 23
States / cities: Little Rock, Arkansas • Orange County, California • San Diego, California + 20 more

Conditions: Brain Arteriovenous Malformation, Brain Vascular Malformations, Vein of Galen Malformation
Interventions: Apollo Micro Catheter device; Device
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: Up to 21 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
Interventions: Finerenone (Kerendia, BAY94-8862); Drug
Lead sponsor: Bayer; Industry
Eligibility: Up to 18 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 22
States / cities: Aurora, Colorado • Wilmington, Delaware • Gainesville, Florida + 18 more

Conditions: Congenital Pseudarthrosis of Tibia
Interventions: NVD003, Iliac Crest Bone Graft; Biological · Procedure
Lead sponsor: Novadip Biosciences; Industry
Eligibility: Up to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Phoenix, Arizona • Loma Linda, California • Baltimore, Maryland + 1 more

Conditions: RENAL INSUFFICIENCY, CHRONIC, LIVER FAILURE, ACUTE, HEART DISEASE
Interventions: ProQuad; Biological
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 6 Months to 24 Months
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Tourette Syndrome in Children, Tourette Syndrome in Adolescence
Interventions: T92, Placebo; Dietary Supplement
Lead sponsor: Tasly Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Pediatric Chronic Inflammatory Demyelinating Polyneuropathy
Interventions: Panzyga; Drug
Lead sponsor: Octapharma; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 6
States / cities: Birmingham, Alabama • Orange, California • Louisville, Kentucky + 3 more

Conditions: Congenital Muscular Dystrophy Due to Lamin A/C Mutation
Interventions: HB-adMSCs; Biological
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: Not listed
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Veno-occlusive Disease
Interventions: Defibrotide, Best Supportive Care; Drug · Other
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 1 Month and older
Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 29 more

Conditions: Congestive Heart Failure
Interventions: Carvedilol; Drug
Lead sponsor: Shaddy, Robert, M.D.; Individual
Eligibility: 1 Day to 17 Years
Enrollment: 75 participants
Timeline: 2002 – 2006
U.S. locations: 17
States / cities: Los Angeles, California • Palo Alto, California • Denver, Colorado + 13 more

Conditions: Malnutrition, Child, Malnutrition, Essential Fatty Acid Deficiency (EFAD), Parenteral Nutrition Associated Cholestasis
Interventions: SMOFlipid® (lipid injectable emulsion); Drug
Lead sponsor: Fresenius Kabi; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 2 more

Conditions: Molybdenum Cofactor Deficiency, Type A
Interventions: ORGN001 (formerly ALXN1101); Drug
Lead sponsor: Origin Biosciences; Industry
Eligibility: Not listed
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder, Asperger's, Pediatric Autism, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Interventions: Memantine Hydrochloride (HCl); Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 906 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 72
States / cities: Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more

Conditions: Recurrent Diffuse Pontine Gliomas
Interventions: nimotuzumab (anti EGFR humanized monoclonal antibody); Biological
Lead sponsor: YM BioSciences; Industry
Eligibility: 3 Years to 18 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 10
States / cities: Denver, Colorado • Washington D.C., District of Columbia • Gainesville, Florida + 6 more

Conditions: Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma, Neuroblastoma
Interventions: chemotherapy, venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 0 Years to 25 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 11
States / cities: San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 8 more

Conditions: Ulcerative Colitis
Interventions: infliximab; Biological
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 18
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more

Conditions: Sickle Cell Anemia
Interventions: ACZ885, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 8 Years to 20 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Atlanta, Georgia • Augusta, Georgia • Greenville, North Carolina

Conditions: Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis, Non-erosive Esophagitis
Interventions: Esomeprazole (Nexium); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 1 Year to 11 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 24
States / cities: Mobile, Alabama • Phoenix, Arizona • Wilmington, Delaware + 21 more

Conditions: Hereditary Angioedema
Interventions: rhC1INH; Drug
Lead sponsor: Pharming Technologies B.V.; Industry
Eligibility: 2 Years to 13 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Hemorrhage
Interventions: TachoSil®, Surgicel® Original; Biological · Device
Lead sponsor: Takeda; Industry
Eligibility: Not listed
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 17
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 14 more

Conditions: Idiopathic Thrombocytopenic Purpura
Interventions: Eltrombopag, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Los Angeles, California • St. Petersburg, Florida • Brooklyn, New York + 1 more

Conditions: Chronic Kidney Disease, Pediatric Urology
Interventions: NSAIDs, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Months to 25 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection

Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries

Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition

Safety of Apollo Micro Catheter in Pediatric Patients

A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

A Study to Assess How Effective and Safe NVD003 is for Treating Patients With Congenital Pseudarthrosis of the Tibia.

Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant

A Clinical Study to Evaluate the Safety and Efficacy of T92 in Pediatric Patients With Tourette Syndrome

Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

HBCMD01- Expanded Access for the Treatment of Congenital Muscular Dystrophy.

Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients

Study to Evaluate the Safety of Twice Daily Oral Carvedilol

Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients

Safety & Efficacy Study of ORGN001 (Formerly ALXN1101) in Pediatric Patients With MoCD Type A Currently Treated With rcPMP

An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia

Esomeprazole for Treatment of GERD in Pediatric Patients

Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients

TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery

Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.

Safety of Short-course of NSAIDs in Pediatric Patients With CKD